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ABSTRACT
Androgen receptor (AR) signaling plays an
important role in the development and progression of prostate cancer (PCa). Importantly,
AR continues to be expressed in advanced
castrate-resistant PCa (CRPC), where the AR can
have ligand-independent activity. Identification of
naturally occurring substances that can inhibit
AR expression holds promise for PCa chemoprevention and therapy. Earlier research demonstrated that resveratrol (Res) inhibited androgenpromoted growth, AR expression, and transactivation in androgen-responsive non-metastatic
LNCaP PCa cells. In the current study, the effects
of Res and three natural analogs [trimethoxyresveratrol (3M-Res), pterostilbene (Pter), and
piceatannol (Pic)] were investigated for effects on
the growth of 22Rv1 castrate-resistant cells that
express full-length (AR114/110) and truncated
form (AR80) of AR. Although all the stilbenes
tested inhibited the proliferation of 22Rv1 cells in
a dose-dependent manner, 3M-Res was the most
potent inhibitor. While AR114/110 responded to
the syn-thetic androgen agonist methyltrienolone
(R1881) as well as to antiandrogen flutamide,
AR80, which lacks a ligand-binding domain, did not
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respond to R1881, but was inhibited by
flutamide. Interestingly, Res, Pter, and Pic, but
not 3M-Res, similar to flutamide, inhibited both
AR114/110 and AR80 with the effect on AR80
being more prominent with the use of high
concentrations of stilbenes. Collectively, the data
indicate that both AR-independent (3M-Res) and
possibly AR-dependent (Res, Pter, and Pic)
mechanisms of cell growth inhibition occurs via
these stilbenes. These findings provide evidence
for plant-derived stilbenes as attractive and
promising pharmacologically safe compounds to
be used for diminishing progression and curb
worsening of CRPC.
INTRODUCTION
Plant-derived polyphenols are attractive clinical
candidates for cancer prevention and treatment.
Resveratrol (Res) (trans-3,5,4'-trihydroxystilbene) is
a polyphenol, a stilbene phytoalexin that is synthesized by a wide variety of plants in response to
environmental stress and other stressors (Bhat and
Pezzuto, 2002). Polygonum cuspidatum (common
name Kojokon) is one such plant that produces Res
(Burns et al., 2002). Res is also produced by grape
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vines (Vitis vinifera), primarily in the grape berry
skin (Fremont, 2000).
Pterostilbene (Pter) (trans-3,5-dimethoxy-4’hydroxystilbene), a natural analog of Res, is a
constituent in blueberries and grapes (Rimando et al.,
2004), and trimethoxy-resveratrol (3M-Res) (trans3,5,4’-trimethoxystilbene) is a constituent in
Pterobolium hexapatallum (common name Indian
Redwing) (Wang et al., 2010). Another naturally
occurring analog, piceatannol (Pic) (trans-3,4,3’,5’tetrahydroxystilbene), which is a constituent in grapes
and red wine, contains one extra hydroxy group
(Kang et al., 2011). Resveratrol has been widely
studied because of various health benefits associated
with the compound, such as cardiovascular,
neuroprotective, anti-inflammatory, antioxidant, and
anticancer effects (Athar et al., 2007; Harikumar and
Aggarwal, 2008; Markus and Morris, 2008; Pirola
and Frojdo, 2008). In recent years natural analogs of
Res have attracted increasing attention as a number of
studies have suggested that modifications to the
chemical structure, such as methoxylationhydroxylation (Fig. 1) could enhance bioactivity
(Huang et al., 2007; Kondratyuk et al., 2011; Wilson
et al., 2008; Gosslau et al., 2008).

Figure 1. Chemical structures of natural stilbenes used in this
study.
Resveratrol (Res), trans-3,4,5’-trihydroxystilbene; Pterostilbene
(Pter), trans-3,5-dimethoxystilbene; Trimethoxy-Resveratrol
(3M-Res), trans—3,5,4”-trimethoxystilbene; Piceatannol (Pic),
trans-3,5,3’4’-tetrahydroxystilbene.

Prostate carcinoma, the most commonly
diagnosed cancer in men in the Western countries,
represents a public health problem with unmet
therapy. Signaling through the androgen receptor
(AR) plays an essential role in the initiation and
progression of prostate cancer. Androgen-deprivation therapy (ADT) is used as a first-line treatment
for metastatic prostate cancer, in which AR continues
to be expressed and active. After significant clinical
response, however, patients with advanced prostate
cancer consistently relapse with a more aggressive
form of PCa known as castration-resistant PCa
(CRPC).
Several mechanisms have been suggested to
mediate AR reactivation during CRPC progression,
including AR gene amplification or overexpression,
expression of splice variants, AR mutations – all of
these conferring ligand promiscuity and/or ligandindependent activity that lead to cancer cell proliferation. Since the available anti-androgens have
low affinity for AR and cannot completely block
androgen action, especially in the presence of
increased AR levels and AR variants, the discovery
of novel potent and antagonistic blockers of AR is
very important.
Kai and Levenson (2011) have previously
demonstrated that Res inhibits the activity and
decreases levels of AR in the androgen-dependent
cell line LNCaP. The AR in these cells bear a
mutation T877A in the ligand binding domain that
affects the response to androgens and anti-androgens
(Mahmoud et al., 2013; Otsuka et al., 2011).
Although initially isolated from lymph node
metastasis, LNCaP cells in tissue culture represent a
relatively “non-aggressive” stage of PCa as these
cells form tumors with much difficulty and do not
form metastasis in xenografts.
In contrast, 22Rv1 cells are castrate-resistant
cells derived from a xenograft that was serially
propagated in mice after castration-induced
regression and relapse of the parental, androgendependent CWR22 xenograft (Sramkoski et al.,
1999). In pathophysiology, this represents a late,
aggressive stage of PCa expressing 114/110 kDa fulllength and truncated 80 kDa AR variants (Guo et al.,
2009).
2
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The goal of the current study was to examine
the effects of Res and the natural analogs of Res (3MRes, Pic, and Pter) as potential new AR blockers in
22Rv1 cells. In this study, Res and Res analogs
inhibited cell proliferation and full-length as well as
truncated AR expression in 22Rv1 cells. The
inhibitory effect on truncated AR levels was most
prominent at the higher concentrations of the tested
compounds. The study results provide substantial
evidence for plant-derived stilbenes as promising
compounds for use, probably in combination with
other anti-androgens, as inhibitors of AR signaling
and thereby diminishing progression and worsening
of CRPC.
MATERIALS AND METHODS
Chemicals. Resveratrol (Res) and piceatannol
(Pic) were purchased from Sigma-Aldrich (St. Louis,
MO) and Calbiochem-Novabiochem (San Diego,
CA), respectively. Trimethoxy-resveratrol (3M-Res)
and pterostilbene (Pter) were chemically synthesized
at the USDA, ARS, National Products Utilization
Research Unit in Oxford, MS, as previously
described (Paul et al., 2010; Rimando et al., 2002).
Structures of the synthesized compounds were
confirmed by nuclear magnetic resonance
spectroscopy and mass spectrometry. All compounds had ≥ 99% purity and were dissolved in high
purity DMSO and stored in the dark at -200C.
Cell culture. The 22Rv1 cells were grown in
RPMI 1640 media (GIBCO, Grand Island, NY)
containing 10% Fetal Bovine Serum (GIBCO, Grand
Island, NY) and 1% antibiotic-antimycotic (GIBCO,
Grand Island, NY) at 37oC and 5% CO2 as previously
described for other prostate cancer cells (Dias et al.,
2013). For experiments involving treatment with Res
and analogs, media was replaced with phenol red-free
RPMI-1640 (GIBCO, Grand Island, NY) containing
5% charcoal-stripped serum (GIBCO, Grand Island,
NY) at least 8-10 h prior to treatment to eliminate
hormonal background.
Cell proliferation assay. Cell viability was
measured by the 3-(4,5-dimethylthazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay. Briefly,
22Rv1 cells were seeded at 3x103 cells/well density in
96-well plates using usual media. The media was
changed to phenol red-free with 5% charcoal-stripped
3

serum 8-10 h prior to treatment. Fresh media (100
μL), containing serial concentrations of Res, 3M-Res,
Pter, and Pic, was added each day for 72 h, after
which 20 μL of 5 mg/mL MTT (Sigma-Aldrich, St.
Louis, MO) was added to the treatment media in the
cells. After a 4 h incubation at 370 C, the media
containing MTT was removed and the formazan
crystals were dissolved in 100 μLof solvent (4 mM
HCl and 0.1% TritonX-100 in isopropanol). The
absorbance of the formazan at 590 nm was measured
using Synergy-4 plate reader (BioTek Instruments
Inc., Winooski, VT). IC50 values were calculated by
the linear interpolation method, using MS Excel
software (Microsoft, Redmond, WA).
Western blot analysis. Western blot analysis
was done as described previously (Dias et al., 2013;
Li et al., 2013). Briefly, 22Rv1 cells at 50-60%
confluency were treated with selected concentrations
of Res and Res analogs for 24 h. The cells were
subsequently lysed in RIPA buffer (ThermoFisher,
Waltham, MA) containing protease and phosphatase
inhibitor cocktail (ThermoFisher, Waltham, MA).
The protein concentration in the lysates was
measured using the Bio-Rad protein assay reagent
(Bio-Rad Laboratories, Hercules, CA). Equal
amounts of protein (50 μg) were resolved in 10%
SDS-PAGE gel and transferred to a PVDF membrane
by Mini-Trans-Blot Electrophoresis Transfer System.
The membranes were subsequently probed with AR
(N20) antibody (Santa Cruz Biotechnology, Dallas,
TX). β-actin (Santa Cruz Biotechnology, Dallas, TX)
was used as a loading control. Signals were
visualized using the chemiluminescent substrate
Super-signal West Dura (ThermoFisher, Waltham,
MA).
Densitometry was done using Image J
software.
Statistical analysis. The differences between
the values of experimental and control treatments
were analyzed for statistical significance by two-tail
Student t test. The p values ≤0.05 were considered to
be significant.
RESULTS
Prostate cancer inhibition. An examination
on the growth of 22Rv1 castrate resistant prostate
cancer cells treated with Res and the three natural
analogs of Res (3M-Res, Pter, and Pic) was
performed. The cells were treated with various
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concentrations of the analogs (1-100 µM) in phenol
red-free RPMI 1640 media supplemented with 5%
charcoal-stripped FBS for 3 days. After treatment, a
cell proliferation assay was done to assess the growth
inhibitory activity of Res and analogs on 22Rv1 cells.
All the tested compounds inhibited the growth of
22Rv1 cells in a dose dependent manner, but with
different potencies (Fig. 2).

in inhibiting the growth of 22Rv1 cells, supporting
the fact that replacement of all three hydroxy (OH)
substituents with methoxy (OCH3) groups results in a
greater growth inhibitory activity (Dias et al., 2013,
Gosslau et al., 2008).
Resveratrol and analog inhibition of AR.
Since the growth inhibition of the castrate-resistant
prostate cancer cells (22Rv1) by resveratrol and
analogs may be related to modulation of AR, the AR
protein levels were assessed by Western blot analysis
(Fig. 3). The 22Rv1 cells are known to express fulllength 114/110 kDa and truncated (80 kDa) AR
variants (Guo et al., 2009). The 80 kDa AR variant,
which is truncated at the C-terminal, contains Nterminal domain (NTD) and a DNA-binding domain
(DBD), but lacks the ligand-binding domain (LBD)
(Fig. 4A) (Dehm et al., 2011).

Figure 2. The effect of resveratrol and analogs on inhibition
of cell growth.
Supplemental: Resveratrol and analogs inhibited growth of 22Rv1
castrate-resistant prostate cancer cells. Cells were grown in media
containing selected doses of resveratrol (Res), trimethoxy-resveratrol
(3M-Res), pterostilbene (Pter), and piceatannol (Pic). MTT assay was
done with formazan measurements at 72 h. Viable cells were plotted
as a fraction of untreated cells (Ctrl) (which was set to 1). Data
represent the mean ± SE of three independent experiments in which
each treatment (data point) was done in triplicates. Statistical
significance was determined by two-tail Student t test. The p value ≤
0.05 was considered significant. The IC50 values were calculated using
the linear interpolation method with MS Excel software.

The cell growth inhibitory effect of Res and
analog was determined by the IC50 values [50%
inhibitory effect cell proliferation], using the liner
interpolation method in MS Excel software. IC50 of
Res 149.92 μM, whereas the other three analogs
exhibited a stronger effect on cell proliferation as
indicated by lower IC50 values of 19.42, 13.88, and
9.45 µM for Pter, Pic, and 3M-Res, respectively. The
3M-Res was the most potent among the Res analogs

Figure 3. Inhibition of AR expression in 22Rv1 castrate
resistant prostate cancer cells.
Supplemental: Western blots (left) indicate the effect of (A) Res, (B) Pter,
and (C) Pic on AR protein levels at selected concentrations along with 10
nM R1881 (synthetic androgen); and 100 μM FL (flutamide - antiandrogen) for 24 h. -actin was used as a loading agent. Graphical
representation (right) is from quantitative analysis by Image J software.
AR 80) levels are
Control (Ctrl) was set as 1 and AR ( AR 114/110,
expressed relative to the control. Data represent the mean ± SE of three
independent trials. *Significant at p < 0.05.

The 114/110 kDa AR variant was recognized as
a single band at 110 kDa (AR114/110) while the 80
4
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kDa AR variant (AR80) was recognized separately.
The AR114/110, which has ligand-binding domain,
responded to the ligand, synthetic androgen (R1881),
and the nonsteroidal anti-androgen flutamide (FL), as
indicated by the increase and decrease in AR levels
upon treatment with R1881 and FL, respectively.
AR80, however, did not respond to R1881, but
responded to FL, suggesting different mechanisms of
FL action than binding to the ligand-binding domain
of AR.
Resveratrol treatment decreased AR114/110
levels in these cells, but at a high concentration of
100 µM, whereas AR80 levels were decreased in a
dose dependent manner. Pterostilbene treatment
initiated reduction of both AR114/110 and AR80
levels, but only at the 100 µM concentration. In
contrast, treatment with Pic showed dose dependent
lowering of both AR114/110 and AR80 levels with
the effect being more prominent in the AR80 levels.
The 3M-Res did not produce a reliable dosedependent inhibition of either AR114/110 or AR80
(data not shown). The differential effects of Res and
analogs on AR114/110 and AR80 may be due to
difference in the interaction of these compounds with
specific domains of the AR variants (Fig. 4).
Cumulative analysis of changes in AR levels by
R1881, FL and stilbenes at 50 and 100 μM
concentrations is shown in Fig. 4B.
DISCUSSION
A mainstay therapy of prostate cancer depends
on androgen deprivation to which most patients do
respond, but relapse with a castrate-resistant clinical
outcome. The AR remains constitutively active in
several cases of CRPC, however, several cellular and
molecular alterations are related to this post-castration
activation of the AR, including in-complete blockade of
AR-ligand signaling,
AR ampli-fications, AR
mutations, aberrant AR co-regulator activities and AR
splice-variant expression (Karantanos et al., 2013).
Accumulating data suggests that both AR-dependent
and AR-independent mechanisms are active and
contribute to castrate-resistance (Kobayashi et al.,
2013).

5

Figure 4. Regulation of full- length and truncated AR levels
in 22Rv1 cells by resveratrol and analogs.
Supplemental: A. Domain structure of full-length AR (110 kDa) and
truncated AR (80 kDa) protein in 22Rv1 cells. B. Graphical representa-tion
of western blots quantitated by Image J software. Res, 3M-Res, Pter, and
Pic reduced the full-length AR (AR114/110) and truncated AR (AR80) levels
at 50 M (left) and 100 M (right) concentrations. R1881 is a synthetic
androgen agonist, and Fl (flutamide is an anti-androgen. Data
represent the mean ± SE of three independent replicate trials, *P<0.05.

In the present study, the effect of Res and
natural Res analogs on full-length and truncated AR
in 22Rv1 cells were investigated. The 22Rv1 cells
are unique in harboring splice variants of AR lacking
the ligand-binding domain (Tepper et al., 2002) that
is frequently expressed (Libertini et al., 2007). This
AR is up-regulated in prostate cancer progression and
promotes androgen-independent growth resistance
(Guo et al., 2009). In earlier studies, Res was shown
to induce down-regulation of AR in LNCaP cells
(harboring a point mutation in AR protein) by
inducing protein degradation through the caspase-3
proteolytic pathway (Kai and Levenson, 2011). From
our earlier observations that Res can inhibit AR
expression in LNCaP cells led to consideration
whether Res and Res natural analogs would have a
similar effect on the AR expression in castrateresistant 22Rv1 cells.
Our data revealed that 3M-Res was
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approximately 16-fold the efficiency of Res in
inhibiting proliferation of 22Rv1 cells as indicated by
their IC50 values (Fig. 2). It has been reported that the
truncated isoform of AR (AR80) mediates the ligandindependent AR activity responsible for cell
proliferation (Marcias et al., 2010). Interestingly, all
three analogs were almost equally effective in
inducing growth-inhibitory activity at the higher
concentrations, and were much more potent than Res.
The current data support our earlier observation that
replacement of all three hydroxy (OH) substituents of
Res with methoxy (OCH3) groups results in greater
growth inhibitory activity (Dias et al., 2013).
Thinking that the growth inhibition by Res and
analogs in these cells may be related to modulation of
AR, and to understand the effect of Res and Res
analogs on the dynamics of the AR protein in 22Rv1
cells, the cells were treated with the test compounds
in increasing doses from 5-100 µM and subjected to a
western blot analysis to determine the AR protein
levels. For controls, the cells were also treated with
the synthetic androgen agonist R1881 and the antiandrogen, FL. R1881 enhanced and FL reduced the
expression of AR114/110, while AR80 responded
only to FL. This action could be expected due to the
lack of LBD in AR80. Only Pic demonstrated a dosedependent down-regulation in AR levels, whereas
Res and Pter were effective only at the higher
concentrations. Interestingly, 3M-Res did not produce
any down-regulation of AR (data not shown)
although the 3M-Res was more efficient than the
other stilbenes in inhibiting the proliferation of
22Rv1 cells.
An AR-independent inhibition mechanism
mediated by 3M-Res may be active in these cells. Of
note, the truncated isoform of AR (AR80) was downregulated more efficiently, as compared to the fulllength counterpart, by FL or the stilbenes, suggesting
involvement of mechanisms other than AR binding.
These observations were corroborated by a test
comparison of the relative expression of the fulllength vis-à-vis the truncated AR with all the
stilbenes at 50 and 100 µM concentrations.
Since the truncated AR can be down-regulated
more effectively by the stilbenes than the full-length
AR, this may possibly provide a target for therapeutic
intervention using combinations of Res and Res ana-

logs in patients that relapse after androgen ablation
and present a castration-resistant phenotype.
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